DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites
- PMID: 1570838
- PMCID: PMC1682596
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites
Abstract
Genomic DNA from two families exhibiting the K-variant phenotype of serum butyrylcholinesterase was amplified by PCR and sequenced to determine the molecular basis of this variant. The K-variant phenotype was found to be associated with a DNA transition from guanine to adenine at nucleotide 1615, which caused an amino acid change from alanine 539 to threonine (GCA----ACA; Ala539----Thr). There was a 30% reduction of serum butyrylcholinesterase activity associated with this mutation. Amplification and sequencing of DNA from a random sample of 47 unrelated people gave a frequency of .128 for the K-variant allele. Thus, 1 person in 63 should be homozygous for the K-variant, making the K-variant the most common butyrylcholinesterase variant. The K-variant mutation was also found to be present in 17 (89%) of 19 butyrylcholinesterase genes containing the point mutation which causes the atypical phenotype of butyrylcholinesterase (GAT----GGT; Asp70----Gly). The presence of the K-variant in the same molecule as the atypical variant does not contribute to the qualitative change in the atypical enzyme, but it most likely accounts for the approximately one-third reduction in Vmax of butyrylcholinesterase activity in atypical serum. Two additional point mutations located in noncoding regions of the gene were also observed to be in linkage disequilibrium with the K-variant mutation. As many as four different point mutations have been identified within a single butyrylcholinesterase gene. Inhibition tests of the enzyme in plasma are usually used to distinguish the K-variant from the usual enzyme when the former is present with the heterozygous atypical variant (AK phenotype vs. UA phenotype). Inhibition tests were performed on plasma enzyme from the four possible genotypic combinations of the heterozygous atypical mutation with or without the K-variant mutation on either allele; we found that the AK phenotype was caused by three genotypes (A/K, AK/K, and U/A) and that the UA phenotype was caused by two genotypes (U/A and U/AK).
Similar articles
-
DNA mutations associated with the human butyrylcholinesterase J-variant.Am J Hum Genet. 1992 May;50(5):1104-14. Am J Hum Genet. 1992. PMID: 1349196 Free PMC article.
-
Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families.Pharmacogenetics. 1992 Oct;2(5):234-40. doi: 10.1097/00008571-199210000-00006. Pharmacogenetics. 1992. PMID: 1306123
-
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants.Clin Biochem. 1990 Oct;23(5):423-31. doi: 10.1016/0009-9120(90)90187-y. Clin Biochem. 1990. PMID: 2253336
-
Identification of human plasma cholinesterase variants using molecular biological techniques.Acta Anaesthesiol Scand. 1995 Feb;39(2):142-9. doi: 10.1111/j.1399-6576.1995.tb04033.x. Acta Anaesthesiol Scand. 1995. PMID: 7793178 Review.
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
Cited by
-
Recovery of residual curarization after red blood cell transfusion.Med Sci Monit. 2012 Nov;18(11):CS91-3. doi: 10.12659/msm.883530. Med Sci Monit. 2012. PMID: 23111747 Free PMC article.
-
Recombinant human butyrylcholinesterase as a new-age bioscavenger drug: development of the expression system.Acta Naturae. 2013 Jan;5(1):73-84. Acta Naturae. 2013. PMID: 23556132 Free PMC article.
-
Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.J Med Genet. 2000 Mar;37(3):182-5. doi: 10.1136/jmg.37.3.182. J Med Genet. 2000. PMID: 10699053 Free PMC article.
-
Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.J Mol Neurosci. 2019 Mar;67(3):445-455. doi: 10.1007/s12031-018-1251-7. Epub 2019 Feb 1. J Mol Neurosci. 2019. PMID: 30707402
-
Confirmed Synergy Between the ɛ4 Allele of Apolipoprotein E and the Variant K of Butyrylcholinesterase as a Risk Factor for Alzheimer's Disease: A Systematic Review and Meta-Analysis.J Alzheimers Dis Rep. 2023 Jun 19;7(1):613-625. doi: 10.3233/ADR-220084. eCollection 2023. J Alzheimers Dis Rep. 2023. PMID: 37483326 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous